Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Sigyn Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Sigyn Therapeutics, Inc.

SIGY

Sigyn Therapeutics, Inc.

About Sigyn Therapeutics, Inc.

Sigyn Therapeutics develops medical devices focused on blood purification to treat infectious diseases, sepsis, and inflammatory disorders. Its flagship Sigyn Therapy extracts pathogens, toxins, and cytokines from blood, addressing unmet needs like viral infections, antibiotic resistance, and sepsis. The company also innovates devices to enhance cancer drug delivery and reduce toxicity, targeting global health challenges with broad-spectrum, extracorporeal solutions.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Sigyn Therapeutics, Inc.

1
1
Sigyn Therapeutics, Inc. Sigyn Therapeutics Reports Q3 Financial Results, Net Loss of $2.7 Million

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Sigyn Therapeutics, Inc. Sigyn Therapeutics Reports No Revenue and Increased Losses in Latest Financial Filing

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Sigyn Therapeutics, Inc. Sigyn Therapeutics Reports Q1 2025 Financial Results with Decreased Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Sigyn Therapeutics, Inc. Sigyn Therapeutics Reports No Revenue and $3.34 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Sigyn Therapeutics, Inc. Sigyn Therapeutics Reports Increased Assets, Reduced Net Loss, and Ongoing Funding Concerns in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments